just before the next regularly scheduled payment date, on a date to be determined by the Commission. They must reflect the financial status of the campaign as of the close of business three business days before the due date of the statement and must also contain a brief explanation of each change in the committee's assets and obligations from the most recent NOCO statement. *Id.* 

The Commission will review the revised NOCO statement and adjust the committee's certification to reflect any change in the committee's financial position that occurs after submission of the matching payment request and the date of the revised NOCO statement. The following schedule includes both matching fund submission dates and submission dates for revised NOCO statements.

SCHEDULE OF MATCHING FUND SUB-MISSION DATES AND DATES TO SUB-MIT REVISED STATEMENTS OF NET OUTSTANDING CAMPAIGN OBLIGA-TIONS (NOCO) FOR 2024 PRESI-DENTIAL CANDIDATES

Matching fund submission dates	Revised NOCO submission dates
January 2, 2024 February 1, 2024 March 1, 2024 April 1, 2024 May 1, 2024 June 3, 2024 July 1, 2024 Aug. 1, 2024 September 3, 2024 October 1, 2024 November 1, 2024 January 2, 2025 February 3, 2025 March 3, 2025	December 21, 2023. January 24, 2024. February 22, 2024. March 22, 2024. April 23, 2024. May 23, 2024. June 21, 2024. July 24, 2024. August 23, 2024. September 23, 2024. October 24, 2024. November 21, 2024. December 23, 2024. January 24, 2025. February 21, 2025.

On behalf of the Commission.

### Dara S. Lindenbaum,

Chair, Federal Election Commission. [FR Doc. 2023–10352 Filed 5–15–23; 8:45 am]

BILLING CODE 6715-01-P

### **FEDERAL RESERVE SYSTEM**

### Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as

other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <a href="https://www.federalreserve.gov/foia/request.htm">https://www.federalreserve.gov/foia/request.htm</a>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than May 31, 2023.

A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414:

1. Michael Estes, Debra Estes, Dean Tabor, and Sharon Tabor, all of Fisher, Illinois; Lyndon S. Estes, Westfield, Indiana; Boyd M. Estes, Chicago, Illinois; Tate Estes, Colona, Illinois; and the Lyndon W. Estes-Trust, Champaign, Illinois, Lyndon W. Estes as trustee, Fisher, Illinois; to form the Estes Family Control Group, a group acting in concert, to retain voting shares of Fisher Bancorp, Inc., and thereby indirectly retain voting shares of The Fisher National Bank, both of Fisher, Illinois, and Catlin Bank, Catlin, Illinois.

Board of Governors of the Federal Reserve System.

### Michele Taylor Fennell,

Deputy Associate Secretary of the Board. [FR Doc. 2023–10428 Filed 5–15–23; 8:45 am] BILLING CODE P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial

property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed).

Date: June 20, 2023.

Time: 10:00 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place*: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G54, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Hitendra S. Chand, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G54, Rockville, MD 20852, (240) 627–3245, hiten.chand@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: May 10, 2023.

#### Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–10364 Filed 5–15–23; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

### National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Neurological Sciences Training Initial Review Group; NST–4 Study Section.

Date: June 13, 2023. Time: 10:30 a.m. to 7:30 p.m.